RxDoctor Payments Data

Robert Alonso, MD

Neurology · Indianapolis, INNPI 1548284011

Payments from drug & device makers

$5,602in general payments, 2019–2025

Across 165 payments — averaging $33.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$1K
  • TG Therapeutics, Inc.$1K
  • AstraZeneca$986
  • Novartis$747
  • EMD Serono, Inc.$420
  • Amgen$301
  • plus $914 from 9 others

What the payments were for

  • Consulting fees$3005%
  • Food & beverage$5,28994%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,602 in reported general payments places this provider in the 60th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$42,691
Medicare patients
209
Services billed
250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5012$276,640
CopaxoneGlatiramer Acetate39$251,179
VumerityDiroximel Fumarate27$220,282
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5014$149,942
TecfideraDimethyl Fumarate14$129,759
Glatiramer Acetate41$122,169
ZeposiaOzanimod Hydrochloride11$100,859
Nurtec OdtRimegepant Sulfate76$88,065
IngrezzaValbenazine Tosylate12$87,901
Aimovig AutoinjectorErenumab-Aooe62$72,165
Dimethyl Fumarate46$57,350
Emgality PenGalcanezumab-Gnlm39$38,785
UbrelvyUbrogepant20$23,569
Lamotrigine ErLamotrigine13$14,616
Dalfampridine ErDalfampridine31$13,431

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Zeposia$98$100,85911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 308 neurology providers in Indiana.

Other neurology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →